The integrated transcriptome bioinformatics analysis identifies key genes and cellular components for proliferative

Nan Gao1, Shengli Hao1, Guannan Huang1

  • 1Department of Ophthalmology, The Second Hospital of Tianjin Medical University, Tianjin, China.

Plos One
|November 21, 2022
PubMed

Insights

This study identifies key genes and cellular components involved in Proliferative Diabetic Retinopathy (PDR), a leading cause of blindness. Findings highlight POSTN as a potential therapeutic target for PDR.

Area of Science:

  • Ophthalmology
  • Genetics
  • Bioinformatics

Background:

  • Proliferative Diabetic Retinopathy (PDR) is a major cause of blindness linked to diabetes.
  • The molecular mechanisms underlying PDR pathogenesis remain incompletely understood.
  • RNA sequencing has begun to reveal genes and cellular components involved in PDR.

Purpose of the Study:

  • To identify novel target genes and cellular components in Proliferative Diabetic Retinopathy (PDR).
  • To elucidate the intrinsic molecular mechanisms of PDR using integrated bioinformatics analysis.
  • To discover potential gene signatures and therapeutic targets for PDR.

Main Methods:

  • Integrated analysis of two bulk RNA-sequencing and one single-cell RNA-sequencing dataset from PDR patients and controls.
  • Identification of differentially expressed genes (DEGs) between PDR and control groups.
  • Analysis of ligand-receptor interactions and Protein-Protein Interaction (PPI) networks to identify key proteins.

Main Results:

  • 176 differentially expressed genes (DEGs) were identified between PDR patients and controls.
  • 14 proteins were found in the overlap of ligand-receptor interactions and PPI networks.
  • CD44, ICAM1, and POSTN were identified as PDR-associated proteins, with POSTN potentially acting as a key ligand.

Conclusions:

  • This integrated bioinformatics analysis provides novel insights into PDR molecular mechanisms.
  • POSTN is highlighted as a potential key ligand and therapeutic target for PDR.
  • The identified gene signatures may aid in the future diagnosis and treatment of Proliferative Diabetic Retinopathy.